Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Chidamide reprograms AML-associated macrophages via HDAC3 inhibition to boost CD8+ T cell immunity

View Full Paper
Ask AI
Bookmark
Share

Authors

TZTan ZhiliYZYaling Zheng

Discussion

Loading...

Member takes

Overview

Chidamide boosts CD8+ T cell proliferation by reprogramming tumor-associated macrophages in AML, highlighting its potential as an immunotherapy.

Key Points

  • Chidamide enhances CD8+ T cell proliferation by reprogramming tumor-associated macrophages, indicating a new immunotherapy strategy.
  • After treatment, macrophages show an immune-activated phenotype with increased CCL4, supporting anti-tumor immunity.
  • Analysis of transcriptomic sequencing revealed the activation of inflammatory pathways linked to tumor growth suppression.
  • Finding underscores the potential of histone deacetylase inhibitors in modifying the tumor microenvironment for improved outcomes.],

Cite This Study

Zhili et al. (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dcdbhttps://doi.org/10.1182/blood-2025-1494
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Activation effects of chidamide on BET signaling pathways and the mechanism of  synergistic effect with BET inhibitors in Mantle Cell Lymphoma2025
  2. 2Chidamide-based epigenetic therapy for relapsed/refractory Acute Myeloid Leukemia2025
  3. 3Low-dose chidamide maintenance therapy following allogeneic hematopoietic stem cell transplantation in T-cell acute lymphoblastic leukemia or lymphoma: A phase 2, open-label, multicenter, single-arm trial2025
  4. 4HDAC inhibitors potentiate the efficacy of antineoplastic agents in acute megakaryoblastic leukemia via dual activation of apoptosis and pyroptosis2025
  5. 5Chidamide and cytarabine synergistically treat acute myeloid leukemia: inhibiting ribosome biogenesis via the MYC-RRP9 pathway2025